{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:26Z","timestamp":1790270726819,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072078"],"award-info":[{"award-number":["82072078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Primary Research and Development Plan of Jiangsu Province","doi-asserted-by":"crossref","award":["SBE2020741118"],"award-info":[{"award-number":["SBE2020741118"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Project of Jiangsu Health Commission","award":["ZDA2020012"],"award-info":[{"award-number":["ZDA2020012"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2022YFC2403400"],"award-info":[{"award-number":["2022YFC2403400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Anhui Provincial Key Research and Development Program","award":["2022e07020013"],"award-info":[{"award-number":["2022e07020013"]}]},{"name":"2020 USTC Affiliated Hospital Introduction Project to Medical Leading Technology","award":["2020LXJS 05"],"award-info":[{"award-number":["2020LXJS 05"]}]},{"name":"Beijing Science and Technology Innovation Fund","award":["KC2021-JX-0186-143"],"award-info":[{"award-number":["KC2021-JX-0186-143"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11523-023-00999-x","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T13:02:30Z","timestamp":1697547750000},"page":"869-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China"],"prefix":"10.1007","volume":"18","author":[{"given":"Minmin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"2","key":"999_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ygyno.2021.08.029","volume":"163","author":"Z Wang","year":"2021","unstructured":"Wang Z, Guo E, Yang B, Xiao R, Lu F, You L, et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: cervical, ovarian and uterine cancer. Gynecol Oncol. 2021;163(2):358\u201363.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"999_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"999_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1136596","volume":"11","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang Z, Zhang Z, Wang H, Peng J, Hong L. Burden of ovarian cancer in China from 1990 to 2030: a systematic analysis and comparison with the global level. Front Public Health. 2023;11: 1136596.","journal-title":"Front Public Health"},{"issue":"10","key":"999_CR4","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol. 2012;23(10):2605\u201312.","journal-title":"Ann Oncol"},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3389\/fonc.2020.00954","volume":"10","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, et al. Evaluation of the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer. Front Oncol. 2020;10:954.","journal-title":"Front Oncol"},{"issue":"9","key":"999_CR6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31(9):1148\u201359.","journal-title":"Ann Oncol"},{"issue":"9","key":"999_CR7","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1535-7163.MCT-20-1064","volume":"20","author":"H Zheng","year":"2021","unstructured":"Zheng H, Gao Y, Guo H, Li L, Li Q, Cui H, et al. Real-world experience of olaparib treatment in patients with ovarian cancer: a Chinese multicenter study. Mol Cancer Ther. 2021;20(9):1735\u201342.","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"999_CR8","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"30","key":"999_CR9","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1200\/JCO.20.00799","volume":"38","author":"P DiSilvestro","year":"2020","unstructured":"DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the solo1 trial. J Clin Oncol. 2020;38(30):3528\u201337.","journal-title":"J Clin Oncol"},{"issue":"2","key":"999_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ygyno.2021.12.016","volume":"164","author":"P Harter","year":"2022","unstructured":"Harter P, Mouret-Reynier MA, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Bogner G, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial. Gynecol Oncol. 2022;164(2):254\u201364.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"999_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s11523-018-0604-z","volume":"13","author":"I Eriksson","year":"2018","unstructured":"Eriksson I, Wettermark B, Bergfeldt K. Real-world use and outcomes of olaparib: a population-based cohort study. Target Oncol. 2018;13(6):725\u201333.","journal-title":"Target Oncol"},{"issue":"6","key":"999_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s11523-021-00842-1","volume":"16","author":"J Paik","year":"2021","unstructured":"Paik J. Olaparib: a review as first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 2021;16(6):847\u201356.","journal-title":"Target Oncol"},{"issue":"22","key":"999_CR13","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/jm901188v","volume":"52","author":"P Jones","year":"2009","unstructured":"Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009;52(22):7170\u201385.","journal-title":"J Med Chem"},{"key":"999_CR14","unstructured":"European Medicines Agency. European Medicines Agency decision EMA\/CHMP\/574018\/2017; 2017."},{"key":"999_CR15","unstructured":"Food and Drug Administration. FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers; 2017."},{"key":"999_CR16","unstructured":"National Medical Products Administration. Niraparib has been approved by NMPA with conditions; 2019."},{"key":"999_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","volume":"33","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Gonz\u00e1lez-Martin A, Buckley L, Matulonis UA, Rimel BJ, Wu X, et al. Safety and management of niraparib monotherapy in ovarian cancer clinical trials. Int J Gynecol Cancer. 2023;33:971\u201381.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"999_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2021;32(4):512\u201321.","journal-title":"Ann Oncol"},{"issue":"25","key":"999_CR19","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"key":"999_CR20","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/S0090-8258(22)01298-7","volume":"166","author":"N Li","year":"2022","unstructured":"Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): a randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5). Gynecol Oncol. 2022;166:S50\u20131.","journal-title":"Gynecol Oncol"},{"issue":"22","key":"999_CR21","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"5","key":"999_CR22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636\u201348.","journal-title":"Lancet Oncol"},{"issue":"6","key":"999_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s11523-021-00841-2","volume":"16","author":"A Lee","year":"2021","unstructured":"Lee A. Niraparib: a review in first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 2021;16(6):839\u201345.","journal-title":"Target Oncol"},{"issue":"7","key":"999_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S2213-8587(21)00088-7","volume":"9","author":"R Caleyachetty","year":"2021","unstructured":"Caleyachetty R, Barber TM, Mohammed NI, Cappuccio FP, Hardy R, Mathur R, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(7):419\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"999_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00404-021-06214-4","volume":"305","author":"X Liu","year":"2022","unstructured":"Liu X, Wu Y, Liu P, Zhang X. Developing a validated nomogram for predicting ovarian metastasis in endometrial cancer patients: a retrospective research. Arch Gynecol Obstet. 2022;305(3):719\u201329.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"999_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","volume":"166","author":"MM Hardesty","year":"2022","unstructured":"Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022;166(2):219\u201329.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"999_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40487-021-00167-z","volume":"9","author":"M Akay","year":"2021","unstructured":"Akay M, Funingana I-G, Patel G, Mustapha R, Gjafa E, Ng T, et al. An in-depth review of niraparib in ovarian cancer: mechanism of action, clinical efficacy and future directions. Oncol Ther. 2021;9(2):347\u201364.","journal-title":"Oncol Ther"},{"issue":"1","key":"999_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2022.04.012","volume":"166","author":"RE O'Cearbhaill","year":"2022","unstructured":"O\u2019Cearbhaill RE, P\u00e9rez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, et al. Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA\/ENGOT-OV26\/GOG-3012 study. Gynecol Oncol. 2022;166(1):36\u201343.","journal-title":"Gynecol Oncol"},{"key":"999_CR29","doi-asserted-by":"publisher","first-page":"S619","DOI":"10.1016\/j.annonc.2020.08.958","volume":"31","author":"G Valabrega","year":"2020","unstructured":"Valabrega G, Pothuri B, Oaknin A, Graybill W, S\u00e1nchez AB, McCormick C, et al. 819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2020;31:S619.","journal-title":"Ann Oncol"},{"issue":"3","key":"999_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2018.12.009","volume":"152","author":"M Fabbro","year":"2019","unstructured":"Fabbro M, Moore KN, D\u00f8rum A, Tinker AV, Mahner S, Bover I, et al. Efficacy and safety of niraparib as maintenance treatment in older patients (\u2265 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial. Gynecol Oncol. 2019;152(3):560\u20137.","journal-title":"Gynecol Oncol"},{"key":"999_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3332\/ecancer.2020.1104","volume":"14","author":"G Liposits","year":"2020","unstructured":"Liposits G, Wulff CN, Otland A, Fokdal LU. Olaparib treatment in older patients with ovarian cancer: need for \u2018real-world\u2019 data beyond clinical trials. Ecancermedicalscience. 2020;14:1104.","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"999_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/curroncol29010029","volume":"29","author":"A Pagkali","year":"2022","unstructured":"Pagkali A, Mamais I, Michalinos A, Agouridis AP. Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis. Curr Oncol. 2022;29(1):321\u201336.","journal-title":"Curr Oncol"},{"key":"999_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.987337","volume":"13","author":"J Nie","year":"2022","unstructured":"Nie J, Wu H, Sun L, Ding Y, Luan Y, Wu J. Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China. Front Pharmacol. 2022;13: 987337.","journal-title":"Front Pharmacol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00999-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T09:20:19Z","timestamp":1700644819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00999-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00999-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"5 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the National Natural Science Foundation of China (82072078), the Primary Research and Development Plan of Jiangsu Province (SBE2020741118), the Scientific Research Project of Jiangsu Health Commission (ZDA2020012), the National Key Research and Development Program (2022YFC2403400), the Anhui Provincial Key Research and Development Program (2022e07020013), the 2020 USTC Affiliated Hospital Introduction Project to Medical Leading Technology (2020LXJS 05), and the Beijing Science and Technology Innovation Fund (KC2021-JX-0186-143). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jun Chen and Jingcheng Xu are employees as well as shareholders of  Zai Lab (Shanghai) Co., Ltd, Shanghai, China. The remaining authors declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was performed following the guiding principles of the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice and appropriate legal guidelines for non-interventional and observational studies and approved by the Ethics Committee of Zhongda Hospital, School of Medicine, Southeast University on 9 September 2022 (no.: 2022040092). The study was registered with ClinicalTrials.gov (Registration number: NCT05734911).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"As the study was retrospective and data collection anonymized, the informed consent of patients was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data generated in this study are available upon reasonable request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Minmin\u00a0Z: formal analysis, investigation, writing\u2014original draft, writing\u2014review and editing, visualization. SQ: formal analysis, writing\u2014original draft, writing\u2014review and editing, visualization. XW, PM, ZJ, TZ, XX, Yanling\u00a0Z, BZ, DY, Yang\u00a0Z, WS, AH, Min\u00a0Z, WH, Yingli\u00a0Z, ZS, MJ and ML: investigation, writing\u2014review and editing, visualization. JC and JX: formal analysis, writing\u2014review and editing, visualization. BC: conceptualization, formal analysis, resources, writing\u2014review and editing, visualization, supervision, project administration. Ying\u00a0Z: conceptualization, investigation, resources, writing\u2014original draft, writing\u2014review and editing, visualization, supervision, project administration, funding acquisition. YS: conceptualization, formal analysis, resources, writing\u2014original draft, writing\u2014review and editing, visualization, supervision, project administration, funding acquisition. All authors approved the final submitted version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}